Ann: BENITEC ABSTRACT ACCEPTED FOR AASLD MEETING, page-23

I don't know much at all about this stuff, but was under the impression the vector was the biggest risk for TT034. With the "anti-HCV shRNAs have been expressed in the liver without any drug-related serious adverse effects" what is the risk these shRNA's dont't reduce viral load? Would this last important step in the process be the one most likely to agree with pre-clinical data...and does the transduction indicated to date not derisk other ddRNAi drugs in development...I remember when the share price was over a dollar and they were struggling to find a single recruit...maybe it is all just 5 years to late..Good luck to all invloved.